155 related articles for article (PubMed ID: 12067622)
1. Altered acetylation in polyglutamine disease: an opportunity for therapeutic intervention?
Taylor JP; Fischbeck KH
Trends Mol Med; 2002 May; 8(5):195-7. PubMed ID: 12067622
[TBL] [Abstract][Full Text] [Related]
2. Altered protein acetylation in polyglutamine diseases.
Bodai L; Pallos J; Thompson LM; Marsh JL
Curr Med Chem; 2003 Dec; 10(23):2577-87. PubMed ID: 14529472
[TBL] [Abstract][Full Text] [Related]
3. Polyglutamine disease: acetyltransferases awry.
Hughes RE
Curr Biol; 2002 Feb; 12(4):R141-3. PubMed ID: 11864588
[TBL] [Abstract][Full Text] [Related]
4. Aberrant histone acetylation, altered transcription, and retinal degeneration in a Drosophila model of polyglutamine disease are rescued by CREB-binding protein.
Taylor JP; Taye AA; Campbell C; Kazemi-Esfarjani P; Fischbeck KH; Min KT
Genes Dev; 2003 Jun; 17(12):1463-8. PubMed ID: 12815067
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
Steffan JS; Bodai L; Pallos J; Poelman M; McCampbell A; Apostol BL; Kazantsev A; Schmidt E; Zhu YZ; Greenwald M; Kurokawa R; Housman DE; Jackson GR; Marsh JL; Thompson LM
Nature; 2001 Oct; 413(6857):739-43. PubMed ID: 11607033
[TBL] [Abstract][Full Text] [Related]
6. [Molecular biology of polyglutamine diseases].
Owecki M; Kozubski W
Postepy Hig Med Dosw; 2002; 56(6):779-88. PubMed ID: 12661407
[TBL] [Abstract][Full Text] [Related]
7. [Mechanisms of neurodegeneration in polyglutamine diseases].
Tsuji S
Rinsho Shinkeigaku; 2003 Nov; 43(11):901-2. PubMed ID: 15152498
[TBL] [Abstract][Full Text] [Related]
8. Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases.
Ghosh S; Feany MB
Hum Mol Genet; 2004 Sep; 13(18):2011-8. PubMed ID: 15254017
[TBL] [Abstract][Full Text] [Related]
9. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies.
Bauer PO; Nukina N
J Neurochem; 2009 Sep; 110(6):1737-65. PubMed ID: 19650870
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders.
Butler R; Bates GP
Nat Rev Neurosci; 2006 Oct; 7(10):784-96. PubMed ID: 16988654
[TBL] [Abstract][Full Text] [Related]
11. Altered transcription in yeast expressing expanded polyglutamine.
Hughes RE; Lo RS; Davis C; Strand AD; Neal CL; Olson JM; Fields S
Proc Natl Acad Sci U S A; 2001 Nov; 98(23):13201-6. PubMed ID: 11687606
[TBL] [Abstract][Full Text] [Related]
12. A mistranslation-prone transcriptome underlying polyglutamine expansion diseases.
Buhr F; Ciryam PS; Vendruscolo M
Nat Rev Mol Cell Biol; 2021 Sep; 22(9):583-584. PubMed ID: 33833432
[No Abstract] [Full Text] [Related]
13. RNA therapy for polyglutamine neurodegenerative diseases.
Watson LM; Wood MJ
Expert Rev Mol Med; 2012 Jan; 14():e3. PubMed ID: 22293529
[TBL] [Abstract][Full Text] [Related]
14. Allele-selective suppression of mutant genes in polyglutamine diseases.
Liu CR; Cheng TH
J Neurogenet; 2015; 29(2-3):41-9. PubMed ID: 26174158
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of chaperones on polyglutamine diseases.
Kobayashi Y; Sobue G
Brain Res Bull; 2001 Oct-Nov 1; 56(3-4):165-8. PubMed ID: 11719246
[TBL] [Abstract][Full Text] [Related]
16. The expanding role for chromatin and transcription in polyglutamine disease.
Mohan RD; Abmayr SM; Workman JL
Curr Opin Genet Dev; 2014 Jun; 26():96-104. PubMed ID: 25108806
[TBL] [Abstract][Full Text] [Related]
17. TATA-binding protein in neurodegenerative disease.
van Roon-Mom WM; Reid SJ; Faull RL; Snell RG
Neuroscience; 2005; 133(4):863-72. PubMed ID: 15916858
[TBL] [Abstract][Full Text] [Related]
18. Interference of CREB-dependent transcriptional activation by expanded polyglutamine stretches--augmentation of transcriptional activation as a potential therapeutic strategy for polyglutamine diseases.
Shimohata M; Shimohata T; Igarashi S; Naruse S; Tsuji S
J Neurochem; 2005 May; 93(3):654-63. PubMed ID: 15836624
[TBL] [Abstract][Full Text] [Related]
19. Polyglutamine expansion diseases: failing to deliver.
Morfini G; Pigino G; Brady ST
Trends Mol Med; 2005 Feb; 11(2):64-70. PubMed ID: 15694868
[TBL] [Abstract][Full Text] [Related]
20. Spinocerebellar ataxia type 1--modeling the pathogenesis of a polyglutamine neurodegenerative disorder in transgenic mice.
Clark HB; Orr HT
J Neuropathol Exp Neurol; 2000 Apr; 59(4):265-70. PubMed ID: 10759181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
